Citi analyst Joanne Wuensch upgraded Integra LifeSciences to Neutral from Sell with an unchanged price target of $38. While ongoing supply challenges and the Boston remediation will weigh down expectations, these are likely in the stock already, the analyst tells investors in a research note. The firm says it is “unclear how much downside is left” in the shares following the recent underperformance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
- Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases
- Integra LifeSciences launches MicroMatrix Flex
- Integra LifeSciences price target lowered to $42 from $45 at BofA
- Integra LifeSciences price target lowered to $49 from $55 at JMP Securities
